N8 Medical

Executive Summary

N8 Medical is a pre-clinical stage medical device company pioneering CeraShield, an innovative coating designed to prevent hospital-acquired infections (HAIs) on indwelling medical devices and implants. By reducing reliance on antibiotics, the technology directly addresses the growing threat of antimicrobial resistance (AMR). The company's platform has the potential to be applied across a wide range of devices, including catheters and stents, where biofilm formation and infection are major complications. Given that HAIs affect millions of patients annually and contribute to significant morbidity, mortality, and healthcare costs, N8 Medical's solution addresses a clear unmet need. Currently at the pre-clinical stage, the company is focused on advancing its lead candidate through in vivo studies and preparing for regulatory interactions. While no financing or valuation data is available, the company's strong scientific rationale and alignment with global health priorities position it as a compelling early-stage opportunity. Success will depend on demonstrating safety and efficacy in animal models, securing funding for clinical trials, and navigating FDA regulatory pathways. The key risk is the early stage of development, with no clinical data yet generated.

Upcoming Catalysts (preview)

• Q4 2026Completion of In Vivo Efficacy Studies for CeraShield Coating60% success
• Q1 2027Pre-IND Meeting with FDA50% success
• Q2 2027Series A Financing Round45% success